• Something wrong with this record ?

Adjuvant radiotherapy after brain metastasectomy: analysis of consecutive cohort of 118 patients from real world practice

P. Fadrus, V. Vybihal, I. Roskova, I. Selingerova, M. Smrcka, R. Jancalek, J. Sana, O. Slaby, P. Pospisil, L. Hynkova, J. Garcic, R. Belanova, J. Kristek, A. Sprlakova-Pukova, Z. Mackerle, V. Juran, M. Sova, E. Neuman, H. Valekova, R. Lakomy, M....

. 2024 ; 29 (1) : 30-41. [pub] 20240318

Status not-indexed Language English Country Poland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24018372

BACKGROUND: The aim of this retrospective study is to analyze a consecutive cohort of brain metastasis (BM) patients treated off clinical trials through combination of surgery and radiotherapy over the last 15 years in a tertiary neurooncology center. MATERIALS AND METHODS: All BM patients operated between 2007-2019 received adjuvant linac-based radiotherapy categorized to whole brain radiotherapy (WBRT) and tumor bed stereotactic radiotherapy. Survival outcomes and local control was analyzed. RESULTS: In total, 118 patients were enrolled, those with stereotactic radiotherapy (41%) had better baseline characteristics mirrored in longer overall survival (OS) [18 vs. 7.1 months, p < 0.001; hazard ratio (HR) 0.47, p = 0.004] with median follow-up of 58 months. Cumulative incidence for local, distant, and extracranial control was not significantly different between groups, with 12-month cumulative control of 22% vs. 18%, 44% vs. 29%, and 35% vs. 32% for stereotactic and WBRT group, respectively. WBRT was an independent factor for better distal brain control. CONCLUSIONS: Real world data demonstrating significantly better overall survival in patients treated with postoperative targeted radiotherapy compared with postoperative WBRT is presented, with no significant difference in cumulative incidence for local or distant brain control. The majority of patients with targeted radiotherapy had a fractionated dose schedule with outcomes comparable to single-dose radiation trials of postoperative targeted radiotherapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018372
003      
CZ-PrNML
005      
20241016081852.0
007      
ta
008      
241008s2024 pl f 000 0|eng||
009      
AR
024    7_
$a 10.5603/rpor.99362 $2 doi
035    __
$a (PubMed)39165600
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Fadrus, Pavel $u Department of Neurosurgery, University Hospital Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Adjuvant radiotherapy after brain metastasectomy: analysis of consecutive cohort of 118 patients from real world practice / $c P. Fadrus, V. Vybihal, I. Roskova, I. Selingerova, M. Smrcka, R. Jancalek, J. Sana, O. Slaby, P. Pospisil, L. Hynkova, J. Garcic, R. Belanova, J. Kristek, A. Sprlakova-Pukova, Z. Mackerle, V. Juran, M. Sova, E. Neuman, H. Valekova, R. Lakomy, M. Holanek, R. Hrstka, M. Svajdova, K. Polachova, I. Kolouskova, P. Slampa, T. Kazda
520    9_
$a BACKGROUND: The aim of this retrospective study is to analyze a consecutive cohort of brain metastasis (BM) patients treated off clinical trials through combination of surgery and radiotherapy over the last 15 years in a tertiary neurooncology center. MATERIALS AND METHODS: All BM patients operated between 2007-2019 received adjuvant linac-based radiotherapy categorized to whole brain radiotherapy (WBRT) and tumor bed stereotactic radiotherapy. Survival outcomes and local control was analyzed. RESULTS: In total, 118 patients were enrolled, those with stereotactic radiotherapy (41%) had better baseline characteristics mirrored in longer overall survival (OS) [18 vs. 7.1 months, p < 0.001; hazard ratio (HR) 0.47, p = 0.004] with median follow-up of 58 months. Cumulative incidence for local, distant, and extracranial control was not significantly different between groups, with 12-month cumulative control of 22% vs. 18%, 44% vs. 29%, and 35% vs. 32% for stereotactic and WBRT group, respectively. WBRT was an independent factor for better distal brain control. CONCLUSIONS: Real world data demonstrating significantly better overall survival in patients treated with postoperative targeted radiotherapy compared with postoperative WBRT is presented, with no significant difference in cumulative incidence for local or distant brain control. The majority of patients with targeted radiotherapy had a fractionated dose schedule with outcomes comparable to single-dose radiation trials of postoperative targeted radiotherapy.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vybihal, Vaclav $u Department of Neurosurgery, University Hospital Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Roskova, Ivana $u Department of Neurosurgery, University Hospital Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Selingerova, Iveta $u Research Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Smrcka, Martin $u Department of Neurosurgery, University Hospital Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Jancalek, Radim $u Department of Neurosurgery, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Neurosurgery, St. Anne's University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Sana, Jiri $u Department of Biology, Faculty of Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Slaby, Ondrej $u Department of Biology, Faculty of Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Pospisil, Petr $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hynkova, Ludmila $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Garcic, Jan $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Belanova, Renata $u Department of Radiology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Kristek, Jan $u Department of Radiology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Sprlakova-Pukova, Andrea $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University, Brno, Czech Republic
700    1_
$a Mackerle, Zdenek $u Department of Neurosurgery, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Neurosurgery, St. Anne's University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Juran, Vilem $u Department of Neurosurgery, University Hospital Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Sova, Marek $u Department of Neurosurgery, University Hospital Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Neuman, Eduard $u Department of Neurosurgery, University Hospital Brno, Czech Republic $u Department of Neurosurgery, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Valekova, Hana $u Department of Neurosurgery, St. Anne's University Hospital Brno, Brno, Czech Republic $u Department of Neurosurgery, St. Anne's University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Lakomy, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Holanek, Milos $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hrstka, Roman $u Research Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Svajdova, Michaela $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Radiation and Clinical Oncology, General Hospital Rimavska Sobota, Rimavska Sobota, Slovakia
700    1_
$a Polachova, Katerina $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kolouskova, Ivana $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kazda, Tomas $u Research Center for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00154188 $t Reports of Practical Oncology and Radiotherapy $x 1507-1367 $g Roč. 29, č. 1 (2024), s. 30-41
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39165600 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081847 $b ABA008
999    __
$a ok $b bmc $g 2196544 $s 1230325
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 29 $c 1 $d 30-41 $e 20240318 $i 1507-1367 $m Reports of Practical Oncology and Radiotherapy $n Rep Pract Oncol Radiother $x MED00154188
LZP    __
$a Pubmed-20241008

Find record

Citation metrics

Archiving options